Warning letter · FDA Warning Letters, Historical Archive

Project 1600 Inc.: FDA Warning Letter 608349 (Jun 18, 2020)

Agency action: Jun 18, 2020Record ID: fda_warning_-e573ea16b59cebd7
View official source ↗

What happened

Original notice title

Project 1600 Inc. MARCS-CMS 608349, June 18, 2020

From the archived source record

Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Some examples of the claims on your website, [see original source] that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include: “NEW! WHY TO BUY THE BOOST PACK: Studies suggest that CBD can help fight off inflammation, boost the immune system, and help battle against certain harmful bacteria. Some research suggests it can help suppress the cytokine storm inside the body that can cause great illness and sometimes death. . . . To help our customers get a full CBD experience that aims to boost your immune system, we offer the ‘DML CBD Immune Boost’ package . . ..” You should take immediate action to correct the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act . Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to correct these violations.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
2fd674d83c5d

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
the ‘DML CBD Immune Boost’ package; 3000mg CBD TINCTURE
Company
Project 1600 Inc.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.